Homology Modeling, Structural Validation, Active Site Identification, and Binding Pocket Analysis of Leishmania major Spermidine Synthase, An in Silico Structural Characterization Study

Main Article Content

Ajazulhaq Haqmal
Zardar Khan
Shamsurrahman Shams
Neak Mohammad Momand
Sayeed Kashif Sayeedi
Mohammad Aslam Bik Danishmal
Sher Azam Khan Awrangzai
Marwan Ahmad

Abstract

Background: Leishmaniasis remains a major global health challenge due to limited therapeutic options and emerging drug resistance. Leishmania major spermidine synthase (SPDS) is an essential enzyme in polyamine biosynthesis, serving as a critical precursor for the trypanothione antioxidant system. Despite its importance for parasite viability and its absence in human hosts, the three-dimensional architecture of L. major SPDS remains experimentally unresolved. Structural characterization is therefore imperative to facilitate the rational design of selective inhibitors targeting this vital metabolic pathway.


Methods: The tertiary structure was predicted via homology modeling using the SWISS-MODEL server and validated through ERRAT, PROCHECK, and Verify3D analysis. Conserved domains were identified using NCBI CD-Search. Binding pockets were characterized via PrankWeb and DoGSiteScorer while potential active site residues were determined through structural comparison with ligand-associated homologous templates and UniProt-annotated catalytic information.


Results: The generated model, based on a Trypanosoma cruzi template (67.92% identity), demonstrated high reliability with a GMQE score of 0.87 and an ERRAT factor of 91.034%. Ramachandran plot analysis showed 99.0% of residues in acceptable regions. Pocket 1 was identified as the primary druggable site, exhibiting a volume of 931.34 ų and a drug score of 0.83. Eleven conserved binding pocket-associated residues and the UniProt-annotated catalytic residue Asp173 were identified within the active region.


Conclusion: This study establishes a high-quality structural framework for L. major spermidine synthase. The identified binding pockets and conserved active-site residues provide essential molecular insights for future virtual screening and structure-based drug discovery efforts aimed at developing potent and selective anti-leishmanial therapeutics.

Article Details

Section
Original Research

References

1. Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018;392(10151):951–70.

2. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5):e35671.

3. World Health Organization. Leishmaniasis [Inter-net]. World Health Organization; 2023 Jan 12 [cited 2026 Nov 8]. Available from: https://www.who.int/news-room/fact-sheets/detail/leishmaniasis

4. Reguera RM, Pérez-Pertejo Y, Gutiérrez-Corbo C, Domínguez-Asenjo B, Ordóñez C, García-Estrada C, et al. Current and promising novel drug candi-dates against visceral leishmaniasis. Pure Appl Chem. 2019;91(8):1385–404.

5. Dufe VT, Ingner D, Heby O, Khomutov AR, Persson L, Al-Karadaghi S. A structural insight into the inhibition of human and Leishmania donovani ornithine decarboxylases by 1-amino-oxy-3-aminopropane. Biochem J. 2007;405(2):261–8.

6. Singh S, Sarma S, Katiyar SP, Das M, Bhardwaj R, Sundar D, et al. Probing the molecular mechanism of hypericin-induced parasite death provides insight into the role of spermidine beyond redox metabo-lism in Leishmania donovani. Antimicrob Agents Chemother. 2015;59(1):15–24.

7. Melcon-Fernandez E, Galli G, García-Estrada C, Balaña-Fouce R, Reguera RM, Pérez-Pertejo Y. Miltefosine and nifuratel combination: a promising therapy for the treatment of Leishmania donovani visceral leishmaniasis. Int J Mol Sci. 2023;24(2):1635.

8. Roberts SC, Jiang Y, Gasteier J, Frydman B, Mar-ton LJ, Heby O, et al. Leishmania donovani polyam-ine biosynthetic enzyme overproducers as tools to investigate the mode of action of cytotoxic polyam-ine analogs. Antimicrob Agents Chemother. 2007;51(2):438–45.

9. Hubin TJ, Walker AN, Davilla DJ, Carder Freeman TN, Epley BM, Hasley TR, et al. Tetraazamacrocy-clic derivatives and their metal complexes as an-tileishmanial leads. Polyhedron. 2019;163:42–53.

10. Wadanambi P. Computational approach to identify potential antileishmanial activity of reported inhibi-tor, E5700 and two natural alkaloids against Leish-mania donovani Squalene Synthase. Exp Results. 2020;1:e31.

11. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev. 2006;19(1):111–26.

12. Sundar S, Singh A. Recent developments and fu-ture prospects in the treatment of visceral leishman-iasis. Ther Adv Infect Dis. 2016;3(3–4):98–109.

13. Ouellette M, Drummelsmith J, Papadopoulou B. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist Updat. 2004;7(4–5):257–66.

14. Fairlamb AH, Cerami A. Metabolism and functions of trypanothione in the Kinetoplastida. Annu Rev Microbiol. 1992;46:695–729.

15. Müller S, Liebau E, Walter RD, Krauth-Siegel RL. Thiol-based redox metabolism of protozoan para-sites. Trends Parasitol. 2003;19(7):320–8.

16. Tabor CW, Tabor H. Polyamines. Annu Rev Bio-chem. 1984;53:749–90.

17. Pegg AE. Mammalian polyamine metabolism and function. IUBMB Life. 2009;61(9):880–94.

18. Roberts SC, Jiang Y, Jardim A, Carter NS, Heby O, Ullman B. Genetic analysis of spermidine synthase from Leishmania donovani. Mol Biochem Parasitol. 2001;115(2):217–26.

19. Ilari A, Fiorillo A, Baiocco P, Poser E, Angiulli G, Colotti G. Targeting polyamine metabolism for finding new drugs against leishmaniasis: a review. Mini Rev Med Chem. 2015;15(3):243–52.

20. Heby O, Roberts SC, Ullman B. Polyamine biosyn-thetic enzymes as drug targets in parasitic protozoa. Biochem Soc Trans. 2003;31(2):415–9.

21. Boitz JM, Yates PA, Kline C, Gaur U, Wilson ME, Ullman B, et al. Leishmania donovani ornithine de-carboxylase is indispensable for parasite survival in the mammalian host. Infect Immun. 2009;77(2):756–63.

22. Willert EK, Phillips MA. Regulated expression of an essential allosteric activator of polyamine biosyn-thesis in African trypanosomes. PLoS Pathog. 2008;4(10):e1000183.

23. Carter NS, Kawasaki Y, Nahata SS, Elikaee S, Ra-jab S, Salam L, et al. Polyamine metabolism in Leishmania parasites: a promising therapeutic tar-get. Med Sci (Basel). 2022;10(2):24.

24. Gilroy C, Olenyik T, Roberts SC, Ullman B. Sper-midine synthase is required for virulence of Leish-mania donovani. Infect Immun. 2011;79(7):2764–9.

25. Birkholtz LM, Williams M, Niemand J, Louw AI, Persson L, Heby O. Polyamine homoeostasis as a drug target in pathogenic protozoa: peculiarities and possibilities. Biochem J. 2011;438(2):229–44.

26. Roberts SC, Scott J, Gasteier JE, Jiang Y, Brooks B, Jardim A, et al. S-adenosylmethionine decarbox-ylase from Leishmania donovani. Molecular, genet-ic, and biochemical characterization of null mutants and overproducers. J Biol Chem. 2002;277(8):5902–9.

27. Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, Appel RD, et al. Protein identification and analysis tools on the ExPASy server. In: Walker JM, editor. The proteomics protocols handbook. To-towa: Humana Press; 2005. p. 571–607.

28. Jones DT. Protein secondary structure prediction based on position-specific scoring matrices. J Mol Biol. 1999;292(2):195–202.

29. Geourjon C, Deléage G. SOPMA: significant im-provements in protein secondary structure predic-tion by consensus prediction from multiple align-ments. Comput Appl Biosci. 1995;11(6):681–4.

30. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol. 2011;7:539.

31. McGuffin LJ, Bryson K, Jones DT. The PSIPRED protein structure prediction server. Bioinformatics. 2000;16(4):404–5.

32. Garnier J, Gibrat JF, Robson B. GOR method for predicting protein secondary structure from amino acid sequence. Methods Enzymol. 1996;266:540–53.

33. Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 2018;46(W1):W296–303.

34. Colovos C, Yeates TO. Verification of protein struc-tures: patterns of nonbonded atomic interactions. Protein Sci. 1993;2(9):1511–9.

35. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr. 1993;26(2):283–91.

36. Haqmal, A., Momand, Z. K., & Aftab, S. (2026). Structural modeling of Luciferin 4-Monooxygenase from Human Respiratory Syncytial Virus using homology techniques. Spinghar Journal of Biomed-ical Science, 2(1), 80–95. https://doi.org/10.64444/sjbs.21.

37. Benkert P, Biasini M, Schwede T. Toward the es-timation of the absolute quality of individual pro-tein structure models. Bioinformatics. 2011;27(3):343–50.

38. Marchler-Bauer A, Derbyshire MK, Gonzales NR, Lu S, Chitsaz F, Geer LY, et al. CDD: NCBI's con-served domain database. Nucleic Acids Res. 2015;43(D1):D222–6.

39. Tian W, Chen C, Lei X, Zhao J, Liang J. CASTp 3.0: computed atlas of surface topography of pro-teins. Nucleic Acids Res. 2018;46(W1):W363–7.

40. Amano Y, Namatame I, Tateishi Y, Honboh K, Tanabe E, Niimi T, et al. Structural insights into the novel inhibition mechanism of Trypanosoma cruzi spermidine synthase. Acta Crystallogr D Biol Crystallogr. 2015;71:1879–89.

41. Volkamer A, Kuhn D, Rippmann F, Rarey M. DoGSiteScorer: a web server for automatic binding site prediction, analysis and druggability assess-ment. Bioinformatics. 2012;28(15):2074–5.

42. Jendele L, Krivak R, Skoda P, Novotny M, Hoksza D. PrankWeb: a web server for ligand binding site prediction and visualization. Nucleic Acids Res. 2019;47(W1):W345–9.

43. Sarma M, Borkotoky S, Dubey VK. Structure-based drug designing against Leishmania donovani using docking and molecular dynamics simulation studies: exploring glutathione synthetase as a drug target. J Biomol Struct Dyn. 2024;42(14):7628–36.

44. Vidhya VM, Dubey VK, Ponnuraj K. Identification of two natural compound inhibitors of Leishmania donovani spermidine synthase (SpdS) through mo-lecular docking and dynamic studies. J Biomol Struct Dyn. 2018;36(10):2678–93.

45. Khare P, Gupta AK, Gajula PK, Sunkari KY, Jaiswal AK, Das S, et al. Identification of novel S-adenosyl-L-homocysteine hydrolase inhibitors through homology-model-based virtual screening, synthesis, and biological evaluation. J Chem Inf Model. 2012;52(3):777–91.

46. Sakyi PO, Broni E, Amewu RK, Miller WA III, Wilson MD, Kwofie SK. Homology modeling, de novo design of ligands, and molecular docking identify potential inhibitors of Leishmania donovani 24-sterol methyltransferase. Front Cell Infect Mi-crobiol. 2022;12:859981.

47. Sheikh SY, Ansari WA, Hassan F, Faruqui T, Khan MF, Akhter Y, et al. Drug repositioning to discover novel ornithine decarboxylase inhibitors against visceral leishmaniasis. J Mol Recognit. 2023;36(7):e3021.

48. Kar RK, Ansari MY, Suryadevara P, Sahoo BR, Sahoo GC, Dikhit MR, et al. Computational eluci-dation of structural basis for ligand binding with Leishmania donovani adenosine kinase. Biomed Res Int. 2013;2013:609289.

49. Sakyi PO, Kwofie SK, Tuekpe JK, Gwira TM, Bro-ni E, Miller WA III, et al. Inhibiting Leishmania do-novani sterol methyltransferase to identify lead compounds using molecular modelling. Pharma-ceuticals (Basel). 2023;16(3):330.

50. Vadloori B, Sharath AK, Prabhu NP, Maurya R. Homology modelling, molecular docking, and mo-lecular dynamics simulations reveal the inhibition of Leishmania donovani dihydrofolate reductase-thymidylate synthase enzyme by Withaferin-A. BMC Res Notes. 2018;11:246.

51. Viana JO, Weber KC, da Cruz LEG, Santos RO, Rocha GB, Jordão AK, et al. In silico structural in-sights and potential inhibitor identification based on the benzothiazole core for targeting L. major pteri-dine reductase 1. ACS Omega. 2025;10(1):306–17.

52. Rajasekaran R, Chen YPP. Probing the structure of L. major DHFR TS and structure based virtual screening of peptide library for the identification of anti-leishmanial leads. J Mol Model. 2012;18:4089–100.

53. Challapa-Mamani MR, Tomás-Alvarado E, Espino-za-Baigorria A, León-Figueroa DA, Sah R, Rodri-guez-Morales AJ, et al. Molecular docking and mo-lecular dynamics simulations in related to Leishma-nia donovani: an update and literature review. Trop Med Infect Dis. 2023;8(10):457.

54. Shakoori AM, Alhakami F, Sindi G, Alyahyawi AY, Alhazzaa RA. Molecular docking of dauno-rubicin and etoposide drugs against Leishmania do-novani: a theoretical study. J Vector Borne Dis. 2024;61(3):369–75.

55. Singh S, Prajapati VK. Exploring actinomycetes natural products to identify potential multi-target inhibitors against Leishmania donovani. 3 Biotech. 2022;12(9):235.

56. Bora K, Sarma M, Kanaujia SP, Dubey VK. Dual-target drugs against Leishmania donovani for poten-tial novel therapeutics. Sci Rep. 2023; 13:18363.

57. Wadanambi PM, Mannapperuma U. Computa-tional study to discover potent phytochemical in-hibitors against drug target, squalene synthase from Leishmania donovani. Heliyon. 2021;7(6):e07178.

58. Arthur MN, Hanson G, Broni E, Sakyi PO, Men-sah-Brown H, Miller WA III, et al. Natural product identification and molecular docking studies of L. major pteridine reductase inhibitors. Pharmaceuti-cals (Basel). 2025;18(1):6.

59. Mansuri R, Diwan A, Mundotiya PK, Singh J. Structural analysis and in-silico inhibitor interaction studies of Leishmania donovani heat-shocked pro-teins 83 (HSP83). Int J Life Sci Pharma Res. 2023;13(Suppl 1):P8–18.

60. Arya PK, Barik K, Kumar A. Targeting spermidine synthase in Leishmania donovani: molecular dock-ing and molecular dynamics simulation-based eval-uation of Indian medicinal plant phytochemicals. In Silico Pharmacol. 2026;14(1):12.